Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextromethorphan + pirfenidone in fibrotic interstitial lung disease
ChiCTR2600126152Phase 4Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pirfenidone and dextromethorphan in pulmonary fibrosis (PF) and interstitial pneumonia (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoints: Chest HRCT and Pulmonary function. Started Jun 2026; status: recruiting.
02
Drugs
pirfenidonedextromethorphan
03
Conditions
pulmonary fibrosis (PF)interstitial pneumonia
Beyond the preview
Go deeper on ChiCTR2600126152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126152.